Mivudvir ®

Mivudvir 150 mg

Composition:

Lamivudine 150 mg.

Indication          

Treatment of HIV-1 Infection.

Dosage and administration

  • Adults and Adolescents > 16 years of age The recommended oral dose of Lamivudine 150 mg Tablets in HIV-1-infected adults and adolescents > 16 years of age is 300 mg daily, administered as either 150 mg twice daily or 300 mg once daily, in combination with other antiretroviral agents. If lamivudine is administered to a patient infected with HIV-1 and HBV, the dosage indicated for HIV-1 therapy should be used as part of an appropriate .combination regimen
  • 2- Pediatric Patients Lamivudine 150 mg Tablets is available as a scored tablet for HIV-1-infected pediatric patients who weigh ≥ 14 kg and for whom a solid .dosage form is appropriate.

Package and storage

.Carton box containing one blister (PVC/Alu) of 10 tablets and insert leaflet – .

Store at temperature not exceeding 30 °C, in a dry place

To be used under physician supervision -

inquiry